Allogene Therapeutics, Inc. (ALLO)
Automate Your Wheel Strategy on ALLO
With Tiblio's Option Bot, you can configure your own wheel strategy including ALLO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALLO
- Rev/Share -0.0001
- Book/Share 1.7895
- PB 0.7097
- Debt/Equity 0.2109
- CurrentRatio 9.7121
- ROIC -0.5636
- MktCap 277788370.0
- FreeCF/Share -0.9199
- PFCF -1.4022
- PE -1.0839
- Debt/Assets 0.16
- DivYield 0
- ROE -0.565
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ALLO | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 14, 2025 |
| Upgrade | ALLO | Citizens JMP | Market Perform | Mkt Outperform | -- | $5 | March 14, 2025 |
News
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Positive
Allogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, especially for ALLO-316 in solid tumors, could be a major catalyst and validate Allogene's platform for broader indications. Despite immense upside potential, significant risks remain: safety, execution, regulatory uncertainty, and likely dilution due to future fundraising needs.
Read More
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Positive
Allogene Therapeutics continues to advance its pipeline, with notable progress in key clinical trials and upcoming data readouts. The company's financial position remains stable, supported by a strong cash runway and prudent expense management. Key strengths include a differentiated allogeneic CAR-T platform and strategic partnerships, though clinical and regulatory risks remain significant.
Read More
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four upcoming investor conferences in May and June.
Read More
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois.
Read More
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m.
Read More
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
Read More
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases, offering off-the-shelf therapies that reduce costs and treatment times. Cema-cel, Allogene's leading product, shows promise in first-line treatment of large B-cell malignancies, with significant revenue potential and positive clinical trial results. Allogene's financial health is stable, with a cash runway until Q1, 2026, and the company is rated a "Buy" for long-term, high-risk-tolerant investors.
Read More
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Positive
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Read More
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) as a Rapid Communication in the Journal of Clinical Oncology. These results represent the largest dataset of LBCL patients treated with an allogeneic CAR T product and, with a minimum of two years of follow-up, the longest follow-up …
Read More
About Allogene Therapeutics, Inc. (ALLO)
- IPO Date 2018-10-11
- Website https://www.allogene.com
- Industry Biotechnology
- CEO Dr. David D. Chang M.D., Ph.D.
- Employees 226